A Placebo for Schizophrenia?

The placebo effect in clinical trials of the mental disorder has increased over the past decade.

Written byCristina Luiggi
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

FLICKR, ARIANE JURQUET

A study by the US Food and Drug Administration (FDA) that looks back at clinical trials of antipsychotic drugs for schizophrenia carried out between 1991 and 2008 found that while the drugs have proven to be effective, their placebo effect has actually increased in recent years.

Although the reason why placebos seem to be getting stronger in clinical trials carried out after 1999 remains unclear, the trend has effectively decreased the trials’ “treatment effect,” which refers to the difference in outcome observed between patients who received the actual drug and those given a placebo. This is a worry for the industry, since trials with low treatment effects are less likely to make it to market, Reuters reported.

The 32 trials analyzed by the FDA were ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies